Keratinocyte Cancer Therapies Enter the Era of Targeted and Immunotherapy

In the past 5 years, major advancements have been made in the systemic therapy of advanced and metastatic melanoma. As opposed to the robust research and clinical trials in melanoma, progress in the treatment of locally advanced and metastatic keratinocyte cancers (KC), such as cutaneous squamous cell carcinomas (cSCC) and basal cell carcinomas (BCC), has been lagging behind. The first targeted therapy was successfully introduced for advanced BCC using hedgehog pathway inhibitors and demonstrated good responses and a decent adverse effects profile. In this issue of JAMA Dermatology, 3 groups of authors discuss their findings about targeted therapy for sSCC and immunotherapy for cSCC and BCC.

http://ift.tt/2mYUj6g